New product newswire: July 23, 2007

July 23, 2007

New drugs, new generics, OTCs, home health care, health & beauty, et al.

Rx

NEW DRUGS

Xyzal (levocetirizine dihydrochloride) is a once-daily antihistamine from UCB Pharma, Smyrna, Ga., (800) 477-7877, and Sanofi-Aventis, Bridgewater, N.J., (908) 243-6000. It is indicated for rapid, long-lasting symptomatic relief of seasonal and perennial allergic rhinitis and uncomplicated skin manifestation of chronic idiopathic urticaria in adults and children six years of age and older.

Atlanta-based Sciele Pharma has launched Prenate DHA, a prescription multivitamin for improving the nutritional status of women throughout pregnancy and postnatally. The soft gel capsules contain omega-3 fatty acids, nine vitamins and minerals, and a 1-mg folate combination. Sciele can be reached at (800) 461-3696.

NEW INDICATIONS

Lyrica (pregabalin), from Pfizer Inc., New York City, (800) 438-1985, carries a new indication for the management of fibromyalgia. The medication was cleared earlier for postherpetic neuralgia, partial seizures, and pain associated with diabetic nerve damage.

NEW FORMULATIONS

Galderma Laboratories, Fort Worth, (817) 961-5000, is bringing out a new, higher concentration formulation of its topical retinoid acne treatment. Differin Gel (adapalene) 0.3% has three times the concentration of the already available 0.1% formulation of Dif fer in. It will treat moderate to moderately severe acne.

NEW LINE EXTENSIONS

Doak Dermatologics, Fairfield, N.J., (800) 929-9300, is introducing two line extensions. To its Kerol portfolio, Doak is adding Kerol Topical Suspension (50% urea). The preparation contains lactic acid and salicylic acid and is indicated for the treatment of hyperkeratotic conditions-among them dermatitis, psoriasis, xerosis, eczema, and corns and calluses. To its Rosula line, the company is adding Fosula Clarifying Wash (sodium sulfacetamide 10% and sulfur 4%), indicated for the treatment of acne vulgaris, acne rosacea, and seborrheic dermatitis.

NEW GENERICS

Watson Pharmaceuticals, Corona, Calif., (951) 493-5300, will manufacture and market generic Wellbutrin XL Tablets. Wellbutrin is a Biovail product. Bupropion HCl extended-release tablets, indicated for major depressive disorder and seasonal affective disorder, will be available in 300 mg.

Dexmethylphenidate hydrochloride tablets, CII, approved earlier in the year as a generic alternative to Novartis' Focalin, is now available from Teva Pharmaceuticals, North Wales, Pa., (888) TEVA USA. Teva will market the product, which carries an indication for the treatment of attention deficit hyperactivity disorder.